Tambua Mapema Plus

Not Applicable

• Conditions: HIV/AIDS

• Registration Number: PACTR202008859669317
• Lead Sponsor: Division of AIDS DAIDS National Institute of Allergy and Infectious Diseases NIAID National Institutes of Health NIH

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2020-08-07
• Last Update Posted: 29 May 2023

Recruitment & Eligibility

• Status: Other
• Sex: All
• Target Recruitment: 3175

Inclusion Criteria

•age from 18-39 years;
•not previously diagnosed with HIV infection; and
•a score =2 on our risk score algorithm to identify persons at higher risk for AHI, with scoring as follows:
oage 18-29 years (1),
ofever (1),
ofatigue (1),
obody pains (1),
odiarrhea (1),
osore throat (1), and
oGUD (3).
Eligibility criteria for partners of newly diagnosed cases with prevalent or acute HIV include:
•age over 18 years; and
•not previously diagnosed HIV infection.

Exclusion Criteria

Patients not meeting inclusion criteria or those who are not willing or able to participate (e.g., due to illness or time constraints, or at the discretion of the study clinician) will be excluded.

Individuals at high risk for IPV are excluded from the aPS intervention, but eligible for all other components of the study.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
To conduct a proof-of-concept study to determine outcomes of a health facility-based HIV-1 RNA testing intervention to identify acute (i.e., RNA-positive, seronegative or discordant rapid test results) and prevalent (i.e., RNA-positive, seropositive) HIV infection, compared to standard care.